Never has so much been known about how cancer develops, spreads and evades treatment.

Over the past two decades, scientists worldwide have built an exquisitely detailed picture of the genetic mutations that fuel cancer’s destructive path. Yet we still face the enormous challenge of translating these insights into new medicines that can stop cancer.

We are building a fit-to-purpose drug hunting engine by integrating next-generation target identification and drug discovery technologies to solve current cancer care challenges and transform oncology treatment paradigms. Our target-centric approach allows us to discover these therapies in a systematic and sustained way by building our pipeline.

We bring together an unprecedented breadth of expertise and state-of-the art capabilities across biological data science, computational chemistry and chemical proteomics. Our leadership team has vast experience taming novel areas of biology and leading highly focused, productive drug development teams.

Precision Oncology 2.0

Scorpion is building transformative therapies to:

  • Broaden the reach of precision oncology to treat many more patients
  • Provide deeper, more durable responses
  • Better targeting both primary and metastatic tissues while sparing healthy tissues and minimizing side effects
  • Have potential to evade key mechanisms of cancer resistance
Our Drug Hunting Engine


Scorpion will transform cancer treatment by addressing precision oncology’s current limitations in three tracks of pipeline build.

Click on a track to learn more.

THE PROBLEM: These drugs fail patients in three important ways: (1) They hamper patient quality of life and often patients must stop therapy due to the side effects.  (2) Many cannot be given at high doses, limiting efficacy and often leading to treatment resistance. (3) Many of these drugs do not reach important tissues such as the brain, where cancers often metastasize.
OUR SOLUTION: A disciplined commitment to designing exquisitely selective compounds that target only tumor tissue and can reach every cancer cell in the body, including both primary and metastatic lesions. We do this by leveraging our chemical proteomics and computational chemistry capabilities, fully integrated into our drug hunting engine.
THE PROBLEM: The currently identified drivers only scratch the surface of the number of possible cancer vulnerabilities across cancer. Indeed, medical research over the last two decades has produced enormous volumes of genetic and biological data that can reveal novel targets and treatment options for thousands more patients.
OUR SOLUTION: A target-centric, mechanism-agnostic approach, leveraging our leading chemical proteomics and computational chemistry platform to go after non-enzymatic targets that have historically been classified as “undruggable.” Our powerful engine identifies a wide variety of novel compounds, so we can advance the best modality for any given target.
THE PROBLEM: Known cancer drivers in Tracks 1 and 2 encompass only a small fraction of possible targets that could provide better therapeutic options for more patients across tumor types.
OUR SOLUTION: Discovering entirely new categories of vulnerabilities in cancer cells that are critical to their survival but never appear in healthy tissue, opening up the potential for novel treatments that can provide deeper responses, better safety and improved durability for large patient populations. Our massive datasets, next generation data analysis tools and proprietary assays allow us to discover novel dependencies and cancer vulnerabilities, and to target them in hopes of transforming treatment paradigms.